4d Molecular Therapeutics Inc Share Price

NASDAQ: FDMT

Small Cap

$6.80

(+-0.07%)

as on September 16, 2025 at 1:29 am IST

$₹

4d Molecular Therapeutics Inc Stock Performance

as on September 16, 2025 at 1:29 am IST

Day's Low
Day's High
$6.6
Day's Price Range
$6.97
$6.8
2.94%
Downside
2.50%
Upside
52 Week's Low
52 Week's High
$2.24
52-Week Price Range
$17.41
$6.8
67.13%
Downside
156.03%
Upside

4d Molecular Therapeutics Inc share price movements today

Previous Close: $6.81
Open: $6.85
Volume: 969.5K
Day's Low - High: $6.6 - $6.97
52 Week Low - High: $2.24 - $17.41

4d Molecular Therapeutics Inc Historical Returns

1 Month Return: -6.2 %
3 Month Return: + 55.13 %
1 Year Return: -58.09 %
3 Year Return: -26.3 %
5 Year Return: 0 %

4d Molecular Therapeutics Inc Stock Fundamentals & Key Indicators

Check 4d Molecular Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$318.0M

EPS (TTM)

-3.6937

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-7.21

Industry PE ratio

-3.8535542168674697

P/B Ratio

PEG Ratio

EBITDA

-215.8M

Revenue (TTM)

33.0K

Profit Margin

0.00%

Return On Equity TTM

0.00%

4d Molecular Therapeutics Inc Stock Valuation

Track how 4d Molecular Therapeutics Inc P/E has moved over time to understand its valuation trends.

4d Molecular Therapeutics Inc in the last 5 years

Overview
Trends

Lowest (0.00x)

September 15, 2025

Today (-7.21x)

September 15, 2025

Industry (-3.85x)

September 15, 2025

Highest (0.00x)

September 15, 2025

LowHigh

Today’s Price to Earnings Ratio: -7.21x

4d Molecular Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of 4d Molecular Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
4d Molecular Therapeutics Inc	BUY	$318.0M	NA	-7.21	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$61.1B	256.98%	-505.15	-12.96%
Beone Medicines Ltd	NA	$38.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$101.1B	47.85%	28.07	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.4B	-3.43%	14.11	31.37%

Stock Returns calculator for 4d Molecular Therapeutics Inc Stock including INR - Dollar returns

The 4d Molecular Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

4d Molecular Therapeutics Inc investment value today

Current value as on today

₹46,832

Returns

₹53,168

(-53.17%)

Returns from 4d Molecular Therapeutics Inc Stock

₹58,154 (-58.15%)

Dollar Returns*

₹4,985 (+4.99%)

Analyst Recommendation on 4d Molecular Therapeutics Inc Stock

Based on 17 analysts

BUY

94.12%

Buy

5.88%

Hold

0.00%

Sell

Based on 17 analysts, 94.12% of analysts recommend a 'BUY' rating for 4d Molecular Therapeutics Inc. Average target price of $30.4

4d Molecular Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on 4d Molecular Therapeutics Inc.

What analysts predicted

77.63%UPSIDE

Target Price

$30.4

Current Price

$6.8

Analyzed by

17 Analysts

Target

$30.40

4d Molecular Therapeutics Inc target price $30.4, a slight upside of 77.63% compared to current price of $6.8. According to 17 analysts rating.

4d Molecular Therapeutics Inc Stock's Interest Amongst Investors

Search interest for 4d Molecular Therapeutics Inc Stock has decreased by -40% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 17, 2025 to September 16, 2025

Change:-40% versus previous 30 day period

4d Molecular Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	0	0	20	0	0	0	0	0	0	0
Gross Profit	-1	-1	18	-4	-1	-1	0	-1	0	-1
Operating Income	-30	-32	-13	-36	-38	-42	-51	-56	-53	-59
EBITDA	-28	-30	-12	-35	-36	-40	-49	-61	-51	-59
Interest Expense	1	-	-	1	-	-	-	-	-	-
Depreciation	1	1	1	1	1	1	1	1	1	1
Income Before Tax	-28	-29	-10	-32	-32	-34	-43	-49	-47	-54
Income Tax Expense	-1	-1	-3	6	0	-	-	0	-	-
Net Income	-27	-29	-10	-32	-32	-34	-43	-49	-47	-54
Net Profit Margin	-9146.98%	-12391.63%	-50.76%	169910.53%	-115717.86%	-699060.00%	-1461433.33%	-4967100.00%	-342657.14%	-364386.67%

4d Molecular Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	5	14	6	13	18	3	20	0
Gross Profit	-7	-4	-31	-39	18	3	-76	0
Operating Income	-11	-10	-50	-56	-71	-110	-112	-187
EBITDA	-10	-9	-44	-55	-68	-106	-107	-187
Interest Expense	-	-	-	0	3	6	-	-
Depreciation	0	0	1	1	3	3	5	6
Income Before Tax	-11	-9	-49	-56	-71	-107	-100	-160
Income Tax Expense	0	0	3	0	-3	-6	5	-
Net Income	-11	-9	-52	-56	-68	-101	-100	-160
Net Profit Margin	-193.83%	-67.59%	-757.79%	-415.38%	-378.63%	-3230.30%	-486.59%	-434778.38%

4d Molecular Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-29	-10	-32	-32	-34	-43	-49	-47	-54
Operating Cash Flow	-22	-1	-24	-29	-30	-29	-45	-47	-43
Investing Cash Flow	49	29	-6	-263	-73	27	7	31	-13
Financing Cash Flow	130	10	4	318	17	0	0	-	0
Change in Cash	157	39	-26	0	-86	-1	-38	-15	-56

4d Molecular Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-9	-49	-56	-71	-107	-100	-160
Operating Cash Flow	-16	-36	-50	-69	-86	-75	-134
Investing Cash Flow	0	-3	-1	-172	-17	115	-302
Financing Cash Flow	84	-2	278	118	3	156	337
Change in Cash	67	-42	227	-123	-100	196	-99

Global Institutional Holdings in 4d Molecular Therapeutics Inc

Funds	Holdings
RA Capital Management, LLC	9.85%
Bvf Inc	9.85%
BlackRock Inc	9.82%
Goldman Sachs Group Inc	9%
Vanguard Group Inc	5.95%

See all

Insights on 4d Molecular Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 3 months, FDMT stock has moved up by 55.1%
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 1.0K → 15.0K (in $), with an average increase of 49.8% per quarter
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 75.6% return, outperforming this stock by 133.7%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 123.5% return, outperforming this stock by 149.8%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, -47.97M → -54.65M (in $), with an average decrease of 13.9% per quarter

About 4d Molecular Therapeutics Inc

the mission of 4d molecular therapeutics is to design and develop transformative gene therapy products using our proprietary technology to create novel adeno-associated virus variants to be utilized as treatments for serious unmet medical conditions. our products are unlocking the full potential of gene therapy to treat, and potentially cure, genetic diseases. a large number of patients and diseases, who previously were not treatable by gene therapy, will be addressable by 4d products. 4d has one of the deepest and most diverse product pipelines in the gene therapy field. adeno-associated virus (aav) vectors have emerged as a favored delivery vehicle for gene therapy in the human body. they can deliver the genes for therapeutic proteins to accessible tissues in the body and are generally considered safe. several aav gene therapy products are in late-stage clinical development, and one product is approved in the eu (glybera, uniqure). however, these first-generation aav vectors have lim

Organisation	4d Molecular Therapeutics Inc
Headquarters	5858 Horton Street, EmeryVille, CA, United States, 94608
Industry	Healthcare
CEO	Dr. David H. Kirn M.D.
E-voting on shares	Click here to vote

Key Management of 4d Molecular Therapeutics Inc

Name	Title
Dr. John F. Milligan Ph.D.	Executive Chairman
Dr. David H. Kirn M.D.	Co-Founder, CEO & Director
Dr. Scott P. Bizily J.D., Ph.D.	Chief Legal Officer & Corporate Secretary
Dr. Julie Clark M.D., M.S.	Chief Medical Officer
Dr. Liansheng Zhu Ph.D.	Senior Vice President of Biometrics & Data Quality
Dr. Fariborz Kamal Ph.D.	President & COO
Ms. Theresa Janke	Co-Founder & Chief of Staff
Dr. An Song Ph.D.	Chief Translational Medicine Advisor
Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.	Senior VP & Therapeutic Area Head of Pulmonology
Mr. Christopher Paul Simms	Chief Commercial Officer

FAQs

What is 4d Molecular Therapeutics Inc share price today?

4d Molecular Therapeutics Inc share price today is $6.8 as on September 16, 2025 at 1:29 am IST at the close of the market. 4d Molecular Therapeutics Inc share today touched a day high of $6.97 and a low of $6.6.

What is the 52 week high and 52 week low for 4d Molecular Therapeutics Inc share?

4d Molecular Therapeutics Inc share touched a 52 week high of $17.41 on September 19, 2024 and a 52 week low of $2.24 on April 9, 2025. 4d Molecular Therapeutics Inc stock price today i.e. September 16, 2025 at 1:29 am IST is closed at $6.8,which is 60.94% down from its 52 week high and 204.25% up from its 52 week low.

What is 4d Molecular Therapeutics Inc's market capitalisation today?

4d Molecular Therapeutics Inc market capitalisation is $0.00T as on September 16, 2025 at 1:29 am IST.

How to invest in 4d Molecular Therapeutics Inc Stock (FDMT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for 4d Molecular Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in 4d Molecular Therapeutics Inc Shares that will get you 0.2206 shares as per 4d Molecular Therapeutics Inc share price of $6.8 per share as on September 16, 2025 at 1:29 am IST.

What is the minimum amount required to buy 4d Molecular Therapeutics Inc Stock (FDMT) from India?

Indian investors can start investing in 4d Molecular Therapeutics Inc (FDMT) shares with as little as ₹88.141 or $1 (as of September 16, 2025 at 4:41 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in 4d Molecular Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on September 16, 2025 at 4:41 am IST). Based on 4d Molecular Therapeutics Inc share’s latest price of $6.8 as on September 16, 2025 at 1:29 am IST, you will get 1.4706 shares of 4d Molecular Therapeutics Inc. Learn more about fractional shares .